Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
337916-20-0
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Axovant_Sciences
gptkb:Eli_Lilly_and_Company |
| gptkbp:hasMolecularFormula |
C23H29FN2O2
|
| gptkbp:hasSMILES |
CN1CCC(CC1)N(C)CC(C2=CC=C(F)C=C2)C3=CC4=C(C=C3)OCCO4
|
| https://www.w3.org/2000/01/rdf-schema#label |
nelotanserin
|
| gptkbp:intendedUse |
treatment of insomnia
treatment of Parkinson's disease psychosis |
| gptkbp:IUPACName |
(2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(4-fluorophenyl)-N-methyl-N-(1-methylpiperidin-4-yl)ethanamine
|
| gptkbp:mechanismOfAction |
5-HT2C receptor antagonist
5-HT2A receptor antagonist |
| gptkbp:PubChem_CID |
11519436
CHEMBL2103882 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
development discontinued
|
| gptkbp:synonym |
EMD-281014
RVT-101 |
| gptkbp:UNII |
6Q1K1VJ0ZC
|
| gptkbp:bfsParent |
gptkb:Axovant_Sciences
|
| gptkbp:bfsLayer |
7
|